| Literature DB >> 27811320 |
Shannon M Beaty1, Raffael Nachbagauer1, Ariana Hirsh1, Frederic Vigant1, James Duehr1, Kristopher D Azarm1, Alice J Stelfox2, Thomas A Bowden2, W Paul Duprex3, Florian Krammer1, Benhur Lee1.
Abstract
To evaluate the antigenic relationship between bat mumps virus (BMV) and the JL5 vaccine strain of mumps virus (MuVJL5), we rescued a chimeric virus bearing the F and HN glycoproteins of BMV in the background of a recombinant JL5 genome (rMuVJL5). Cross-reactivity and cross-neutralization between this chimeric recombinant MuV bearing the F and HN glycoproteins of BMV (rMuVJL5-F/HNBMV) virus and rMuVJL5 were demonstrated using hyperimmune mouse serum samples and a curated panel of human serum. All mouse and human serum samples that were able to neutralize rMuVJL5 infection had cross-neutralizing activity against rMuVJL5-F/HNBMV. Our data suggest that persons who have neutralizing antibodies against MuV might be protected from infection by BMV.Entities:
Keywords: cross-reactive antibodies; mumps virus; neutralizing antibodies; viral envelope proteins; zoonoses
Mesh:
Substances:
Year: 2017 PMID: 27811320 PMCID: PMC5854012 DOI: 10.1093/infdis/jiw534
Source DB: PubMed Journal: J Infect Dis ISSN: 0022-1899 Impact factor: 5.226